BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38008817)

  • 1. The lived experience of patients with breast cancer on adjuvant endocrine therapy: side effects and coping strategies during the first year of medication initiation.
    Gomaa S; Lopez A; Slamon R; Smith R; Lapitan E; Nightingale G; Miller SM; Wen KY
    Support Care Cancer; 2023 Nov; 31(12):719. PubMed ID: 38008817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The lived experience of breast cancer patients on adjuvant endocrine therapy: Side effects and coping strategies during the first year of medication initiation.
    Gomaa S; Lopez A; Slamon R; Smith R; Telushi E; Lapitan E; Nightingale G; Miller S; Wen KY
    Res Sq; 2023 Jan; ():. PubMed ID: 36778385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testing a behavioral intervention to improve adherence to adjuvant endocrine therapy (AET).
    Shelby RA; Dorfman CS; Bosworth HB; Keefe F; Sutton L; Owen L; Corsino L; Erkanli A; Reed SD; Arthur SS; Somers T; Barrett N; Huettel S; Gonzalez JM; Kimmick G
    Contemp Clin Trials; 2019 Jan; 76():120-131. PubMed ID: 30472215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deconstructing Decisions to Initiate, Maintain, or Discontinue Adjuvant Endocrine Therapy in Breast Cancer Survivors: A Mixed-Methods Study.
    Bluethmann SM; Murphy CC; Tiro JA; Mollica MA; Vernon SW; Bartholomew LK
    Oncol Nurs Forum; 2017 May; 44(3):E101-E110. PubMed ID: 28635973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients.
    Rosso R; D'Alonzo M; Bounous VE; Actis S; Cipullo I; Salerno E; Biglia N
    Curr Oncol; 2023 Jan; 30(2):1461-1472. PubMed ID: 36826073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Partner status moderates the relationships between sexual problems and self-efficacy for managing sexual problems and psychosocial quality-of-life for postmenopausal breast cancer survivors taking adjuvant endocrine therapy.
    Dorfman CS; Arthur SS; Kimmick GG; Westbrook KW; Marcom PK; Corbett C; Edmond SN; Shelby RA
    Menopause; 2019 Aug; 26(8):823-832. PubMed ID: 30994574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The experiences of adjuvant endocrine therapy for women breast cancer survivors: A literature review.
    Long Y; Xie S; Liu Q; Xu F; Li Q; Wang N; Zhang Y
    Medicine (Baltimore); 2023 Dec; 102(51):e36704. PubMed ID: 38134074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between Out-Of-Pocket Costs, Race/Ethnicity, and Adjuvant Endocrine Therapy Adherence Among Medicare Patients With Breast Cancer.
    Farias AJ; Du XL
    J Clin Oncol; 2017 Jan; 35(1):86-95. PubMed ID: 28034069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant therapy use among Appalachian breast cancer survivors.
    Tan X; Marshall VD; Anderson RT; Donohoe J; Camacho F; Balkrishnan R
    Medicine (Baltimore); 2015 Jul; 94(26):e1071. PubMed ID: 26131828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A telehealth intervention for symptom management, distress, and adherence to adjuvant endocrine therapy: A randomized controlled trial.
    Jacobs JM; Post K; Massad K; Horick NK; Walsh EA; Cohn J; Rapoport CS; Clara AJ; Antoni MH; Safren SA; Partridge AH; Peppercorn JM; Park ER; Temel JS; Greer JA
    Cancer; 2022 Oct; 128(19):3541-3551. PubMed ID: 35924869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding pain related to adjuvant endocrine therapy after breast cancer: A qualitative report.
    Walsh EA; Chabria R; Vranceanu AM; Park ER; Post K; Peppercorn J; Temel JS; Greer JA; Jacobs JM
    Eur J Cancer Care (Engl); 2022 Nov; 31(6):e13723. PubMed ID: 36196499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors influencing adherence to adjuvant endocrine therapy in breast cancer-treated women: using real-world data to inform a switch from acute to chronic disease management.
    Cavazza M; Banks H; Ercolanoni M; Cukaj G; Bianchi G; Capri G; Longo F
    Breast Cancer Res Treat; 2020 Aug; 183(1):189-199. PubMed ID: 32591986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic adaptation of the adherence improving self-management strategy to support breast cancer survivors' adherence to adjuvant endocrine therapy: An intervention mapping approach.
    Janssen AM; Dam J; Prins J; Buffart LM; de Bruin M
    Eur J Cancer Care (Engl); 2022 Nov; 31(6):e13721. PubMed ID: 36263723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Patient's Voice: Adherence, Symptoms, and Distress Related to Adjuvant Endocrine Therapy After Breast Cancer.
    Jacobs JM; Walsh EA; Park ER; Berger J; Peppercorn J; Partridge A; Horick N; Safren SA; Temel JS; Greer JA
    Int J Behav Med; 2020 Dec; 27(6):687-697. PubMed ID: 32495240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding adjuvant endocrine therapy persistence in breast Cancer survivors.
    Lambert LK; Balneaves LG; Howard AF; Chia SK; Gotay CC
    BMC Cancer; 2018 Jul; 18(1):732. PubMed ID: 29996816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review.
    Lambert LK; Balneaves LG; Howard AF; Gotay CC
    Breast Cancer Res Treat; 2018 Feb; 167(3):615-633. PubMed ID: 29110151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modifiable risk factors for adherence to adjuvant endocrine therapy among breast cancer patients.
    Jacob Arriola KR; Mason TA; Bannon KA; Holmes C; Powell CL; Horne K; O'Regan R
    Patient Educ Couns; 2014 Apr; 95(1):98-103. PubMed ID: 24492157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing Symptom Distress: Key Factors for Patients on Adjuvant Endocrine Therapy for Breast Cancer.
    Post KE; Ahmad Z; Jankauskaite G; Centracchio J; Oswald L; Horick N; Park ER; Temel JS; Greer JA; Jacobs J
    J Pain Symptom Manage; 2024 Jan; 67(1):88-97. PubMed ID: 37816436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adherence to adjuvant endocrine therapy for breast cancer: a qualitative exploration of attribution of symptoms among post-menopausal women.
    Lee AY; Lyons AT; Makris V; Kamaraju S; Stolley MR; Neuner JM; Flynn KE
    Support Care Cancer; 2024 Apr; 32(4):265. PubMed ID: 38565669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Racial Differences in Patient-Reported Symptoms and Adherence to Adjuvant Endocrine Therapy Among Women With Early-Stage, Hormone Receptor-Positive Breast Cancer.
    Hu X; Walker MS; Stepanski E; Kaplan CM; Martin MY; Vidal GA; Schwartzberg LS; Graetz I
    JAMA Netw Open; 2022 Aug; 5(8):e2225485. PubMed ID: 35947386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.